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Objectives: From the perspective of public health, tuberculosis (TB) remains an
important issue that threatens health. Korea is an intermediate burden country
with a TB incidence of 97/100,000 individuals. Among many TB control measures,
a relapse rate of TB is one indicator that can be used to indirectly assess the level
of TB control in countries and in communities. Relapse TB has an approximately
12% yearly incidence in Korea. This study aims to estimate the relapse rate of TB
and to investigate the associated factors by using nationwide TB notification data
in Korea.
Methods: The nationwide TB notification data in 2005 was used with the exclu-
sion criteria of duplicated reporting, foreign-born patients, outcomeedied, and
outcomeediagnosis changed. The data were double-checked as to whether they
were reported again during 2006e2010 and the estimated relapse rate of TB.
Associated factors were analyzed by multivariate logistic regression with the
variables of age, sex, registration type, results of sputum smear test, medica-
tion, and outcome of treatment.
Results: Among 45,434 TB patients in 2005, 4,371 patients were again reported as
TB patients from 2006 to 2010. Five hundred and sixty-four patients were re-
ported more than twice and the cumulative number of relapses was 5,072 cases.
The 5-year relapse rate was estimated as 9.62%. The relapse rate decreased
yearly: 4.8% in 2006, 2.4% in 2007, 1.6% in 2008, 1.4% in 2009, and 1.0% in 2010.
Age, sex, registration type, tuberculosis type, and medication were indepen-
dently associated with a relapse of TB. In the multivariate logistic regression
analysis, the following factors were related: male sex, 40e49 years old; regis-
tration type, relapse, treatment after failure, treatment after default, transfer
in, and other, the sputum smear-positive pulmonary TB, and medications
(including individuals taking 2e5 drugs).ted under the terms of the Creative Commons Attribution Non-Commercial License (http://
) which permits unrestricted non-commercial use, distribution, and reproduction in any
operly cited.
ase Control and Prevention. Published by Elsevier Korea LLC. All rights reserved.
Relapse of Tuberculosis in Korea S9Figure 1.Conclusion: This study has estimated a 5-year relapse rate of TB in Korea that is
slightly lower than the rate of relapse TB in the annual reports. This study could
be conducted and cross-checked with data from the National Health Insurance in
the future.1. Introduction
Tuberculosis (TB) is an infectious disease caused by
Mycobacterium tuberculosis. It primarily infects the
lungs, but it can also infect the digestive organs, lymph,
and bones. Approximately 10% of the M. tuberculosis-
infected people develop tuberculosis. The onset of
tuberculosis is more frequent in men and tends to in-
crease with aging. People with lower immunity, old age,
diabetes; who use immunosuppressive drugs; and people
with HIV/AIDS infection are more likely to develop
tuberculosis [1].
Tuberculosis remains an important problem that
threatens public health throughout the world, including
Korea. Tuberculosis-infected people in Korea number
an estimated 15 million, which is one-third of the
total population [2]. Each year Korea witnesses
30,000e35,000 newly diagnosed cases of TB, which is
the highest incidence among infectious diseases in
Korea, and approximately 75,000 people are treated
[3,4]. The World Health Organization (WHO) reports a
TB incidence rate of 97 per 100,000 people in Korea, and
Korea is among the intermediate burden countries [1].
Since 1962, Korea has begun to control TB on a
national basis with its National Tuberculosis Control
Plan. The national tuberculosis status survey has been
conducted every 5 years since 1965 until 1995. During
this period, the incidence rate has sharply decreased and
the prevalence rate has also decreased from 5% to 1%Number and rate of tuberc[2]. With a decrease of TB patients and low responding
rate of the national survey, the national TB status has
been identified on a report basis since 2000 [5]. The
scale of TB patients has not been decreased, but remains
steady [3,4] (Figure 1).
Deaths and the incidence rate caused by TB are also
the highest among all infectious diseases. In fact,
because of TB infection, Korea has the highest inci-
dence and deaths among the 36 Organisation for Eco-
nomic Co-operation and Development (OECD)
countries and is 70the90th among WHO member states
[1]. The patients are mostly distributed in their 20e40s
(40%), which is a typical aspect of developing countries.
Tuberculosis in Korea was mostly controlled by public
health centers, but private hospitals have gradually taken
over this role since the mid-1990s, and above 85% of
TB patients are treated and controlled in private hospi-
tals since 2010 [3,4,6].
Tuberculosis relapse is divided into two classes: (1) a
patient in whom the initial onset has been treated, but
the existing M. tuberculosis reactivates into a second
onset of TB; and (2) a patient with reinfection with new
M. tuberculosis [7,8]. To distinguish between these two
classes, genotyping is necessary but unfeasible for every
patient. Korea does not identify these two classes [i.e.,
relapse (reactivated onset) and reinfection] [9]. The
relapse rate differs by a country’s incidence and control:
0e27% of TB relapses occur within 2 years after
treatment completion and most relapses occur within 5ulosis notification in 2001e2010.
S10 H. Lee, J. Kimyears; however, some relapses occur 15 years after
treatment. In low incidence countries, most relapses
occur within 2 years of treatment completion; however,
in high incidence countries, relatively high relapse 2
years after treatment completion can be attributed to the
relatively high chance of reinfection [10e12].
Among many indicators to control TB, the relapse
rate is an indicator that can be used to evaluate a com-
munity’s level of tuberculosis control [13]. According to
the Korea Tuberculosis Annual Report, approximately
12% of annual reported cases are reported as relapse
tuberculosis [3,4]. However, no national level study has
been conducted with the exception of studies on specific
medical institution or TB patients with antimicrobial
resistance. This study aims to estimate the relapse rate of
TB in Korea by using national data on reported cases
and find factors related to the relapse of TB.
2. Materials and methods
2.1. Study participants
The data source is the national reported cases of TB
patients registered in the TB Integrated Information
System (TBnet). The study participants were TB pa-
tients registered in TBnet in 2005. The exclusion criteria
were patients with duplicate reports, foreigners, chronic
TB cases, death after treatment, and changed diagnosis.
Among 46,969 patients registered in TBnet in 2005, the
following were excluded: 718 duplicate reports, 388
foreigners, 49 changed diagnosis, 262 deaths after
treatment, and 118 chronic cases. In this study, 45,434
TB patients were analyzed (Figure 2).
2.2. Methods
We checked whether the patients in the study had
been reported again in the TBnet during the following 5
years (i.e., 2006e2010). We selected the following
variables as related factors in the reported data: age, sex,
region, registration type, disease code (based on the
International Classification of Disease-10, available at
http://apps.who.int/classifications/icd10/), medicine, andFigure 2. Study population.treatment results. The region was classified and coded
from 1 to 16 with no specific region name. Registration
types were “new case”, “relapse”, “treatment after fail-
ure”, “treatment after default”, “transfer in”, or “other”.
The disease codes of the ICD-10 were reclassified as
follows: “sputum smear-positive pulmonary TB”
(A15.0); “sputum smear-negative pulmonary TB”
(A15.1, A15.2, A15.3, A16.0, A16.1, A16.2, A19.0-
A19.9); and “extrapulmonary TB” (A15.4-A15.9,
A16.3-A16.9, A17.x, A18.x). Based on the medication,
patients were divided into five groups: Group 1 patients
were treated with isoniazid, rifampin, pyrazinamide, and
ethambutol. Groups 2e5 patients were classified ac-
cording to the other medicines. Treatment results were
classified as “cure”, “complete”, “failure”, “default”,
“transfer out”, and “others”.
The data used in this study did not require the sub-
mission of informed consent from the patients because
the report is mandatory by the tuberculosis prevention
law. The author received the data with no personal in-
formation and the computer to access the data was not
connected with an outside network. This study was
approved by the Institutional Review Board of the Korea
Centers for Disease Control and Prevention, Cheongju,
Korea (No. 2012-05CON-15-P).
2.3. Data analysis
Descriptive epidemiological analysis was conducted
for the general characteristics of study patients. The Chi-
square test was performed for major variables and
relapse with 0.05 significance level. Multivariate logistic
regression analysis was conducted to analyze factors
associated with relapse of TB. SAS 9.2 for Windows
(SAS Inc., Cary, NC, USA) was used for data analysis.3. Results
3.1. General characteristics and variables
The characteristics of TB patients registered in TBnet
2005 were the following. More than one-half (62.1%) of
the patients were men. The average age was 47.5  19.8
years. Most patients were above the age of 20 years: 214
patients were aged < 10 years; 2,443 patients were aged
10e19 years; 8134 patients were aged 20e29 years;
7,299 patients were aged 30e39 years; 7338 patients
were aged 40e49 years; 5,675 patients were aged
50e59 years; 6,293 patients were aged 60e69 years;
and 8,038 patients were aged  70 years. The registra-
tion types were the following: 34,569 new cases; 5611
relapses; 654 re-registration after cease; 1,812 move-in;
and 2,505 others. There were 15,745 sputum smear-
positive pulmonary TB cases; 23,437 sputum smear-
negative pulmonary TB cases; and 6,216 extrapulmo-
nary TB cases. Group 1 medicines alone were used by
43,276 patients, but 2,158 patients used the other med-
icine groups. Based on age, location of medical
Relapse of Tuberculosis in Korea S11institution, registration type, and TB type, the number of
male patients was statistically significantly greater than
the number of women (Table 1).
3.2. Factors associated with the relapse rate
Among 45,434 patients in 2005, 4,371 persons were
re-reported during the following 5-year period (i.e.,
2006e2010). The total number of re-reported cases was
5072 reports with the exclusion of 564 duplicate reports.
Therefore, the 5-year relapse rate of TB was 9.62, based
on the number of patients. The annual relapse rate
decreased yearly: 2,189 (4.8%) patients in 2005; 1,082
(2.4%) patients in 2007; 714 (1.6%) patients in 2008;
615 (1.4%) patients in 2009; and 472 (1.0%) patients in
2010. The first 2 years had 65% of relapses in the 5-year
period (Figures 3 and 4).
The Chi-square test showed that the relapse rate and
study variables were all independently related. MenTable 1. General characteristics of the study population.
Total
Age (y) 0e9 2
10e19 2,4
20e29 8,1
30e39 7,2
40e49 7,3
50e59 5,6
60e69 6,2
 70 8,0
Region 1 12,0
2 4,5
3 2,1
4 1,8
5 1,3
6 1,0
7 6
8 6,7
9 2,1
10 1,2
11 1,8
12 2,1
13 1,9
14 2,1
15 3,1
16 4
Registration New 34,5
Type Relapse 5,6
T.A.F. 2
T.A.D. 6
T.I. 1,8
Other 2,5
Tuberculosis type Sputum smear (þ) pul TB 15,7
Sputum smear () pul TB 23,4
Extrapulmonary TB 6,2
Medication Only Group 1 drugs 43,2
With Groups 2e5 drugs 2,1
Total 45,4
pul Z pulmonary; T.A.D. Z treatment after default; T.A.F. Z treatment afte(10.86%) more frequently relapsed, compared to women
(7.59%). The relapse rate was highest among patients in
their 40s (11.50%), followed by patients in their 50s
(10.27%), 60s (10.03%), 30s (9.81%), 20s (8.81%), 70s
(8.53%), 10s (7.65%), and < 10 years (3.27%). Patients
(9.87%) in private medical institutions had slightly more
relapses than patients (8.97%) in public health centers.
Patients with re-registration after cease showed the
highest relapse rate (25.08%), followed by failure of the
first treatment (21.55%), relapse (14.95%), others
(12.14%), move-in (10.49), and new cases (8.14%). The
highest relapse rate occurred with sputum smear-
positive pulmonary TB (12.37%), followed by sputum
smear-negative pulmonary TB (8.72%) and extrap-
ulmonary TB (6.05%). More relapsed patients (15.89%)
had used medicines from Group 2 to Group 5, compared
to patients using Group 1 medicines (9.31%). The
location of the medical institutions also showed a(no.) Men (no.) Women (no.) p
14 113 101 < 0.0001
43 1,490 953
34 4,263 3,871
99 4,510 2,789
38 5,251 2,087
75 4,148 1,527
93 4,236 2,057
38 4,197 3,841
85 7,309 4,776 < 0.0001
31 2,799 1,732
55 1,364 791
54 1,186 668
86 850 536
48 637 411
81 432 249
47 4,221 2,526
30 1,206 924
65 787 478
41 1,205 636
01 1,329 772
46 1,247 699
06 1,284 822
57 2,089 1,068
01 263 138
69 20,631 13,938 < 0.0001
11 4,095 1,516
83 214 69
54 496 158
12 1,125 687
05 1,647 858
45 10,251 5,494 < 0.0001
37 14,773 8,700
16 3,184 3,032
76 26,757 16,519 < 0.0001
58 1,451 707
34 28,208 17,226
r failure; T.I. Z transfer in.
Figure 3. Relapse rate of tuberculosis by year (2006e2010).
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the lowest rate was 6.93% (Table 2).
Among TB patient data of public health centers for
which treatment results were available, the relapse rate
was independently associated with sex, age, registration
type, TB type, treatment result and region, based on the
Chi-square test. The relapse rate was higher in men
(10.0%) than in women (6.8%). The age-related relapse
rate showed that the< 10 years age group had the highest
rate (20.0%), followed by patients in their 20s (8.4%);
30s (9.3%); 40s (10.2%); 50s (10.3%); 60s (10.0%); and
70s (7.8%). However, the < 10 year age group size wasFigure 4. Proportion of relapse of tuberculosis by year
(2006e2010).only five patients; therefore, the relapse rate of the group
could not be an effective value. Patients with first treat-
ment failure experienced the greatest relapse (40%),
followed by re-registration (21.2%), relapse (14.9%),
others (10.8%), new cases (7.5%), and move-out (7.4%).
However, the size of first treatment failure group was
also small and insufficient to justify the results.
Based on the tuberculosis type, the relapse rate of
sputum smear-positive pulmonary TB was 11.8%;
sputum smear-negative pulmonary TB, 7.0%; and
extrapulmonary TB, 5.4%. Treatment results showed
that patients with treatment failure had the highest
relapse rate (50%), followed by treatment cease
(24.0%), others (17.1%), move-out (11.4%), completion
(11.1%), and full recovery (7.3%). The regional relapse
rate showed a difference: the highest rate was 12.32%
and the lowest rate was 5.42%.
The Chi-square test showed that the relapse rate in
public health center patients with treatment results were
associated with age, sex, registration type, TB type, and
medicine. With these variables, multivariate logistic
regression was performed to confirm that most related
variables in the Chi-square test were also related.
The relapse rate for all study patients was higher in
men than in women with an odds ratio of 1.33 [95%
confidence interval (95% CI), 1.24e1.43]. Because of
the small size of the < 10-year-old group, the reference
was patients in the 10s age group and the odds ratio of
relapse in the 40s age group was significant at 1.20 (95%
CI, 1.01e1.42); however, the other age groups did not
show a significant difference. Compared to users of
private medical institutions, public health center users
were more likely to relapse with an odds ratio of 1.23
Table 2. Relapse rate of tuberculosis by the characteristics of the study population.
Relapse
pNo Yes
Sex Men 25,145 (89.14) 3,063 (10.86) < 0.0001
Women 15,918 (92.41) 1,308 (7.59)
Age (y) 0e9 207 (96.73) 7 (3.27) < 0.0001
10e19 2,256 (92.35) 187 (7.65)
20e29 7,417 (91.19) 717 (8.81)
30e39 6,583 (90.19) 716 (9.81)
40e49 6,494 (88.50) 844 (11.50)
50e59 5,092 (89.73) 583 (10.27)
60e69 5,662 (89.97) 631 (10.03)
 70 7,352 (91.47) 686 (8.53)
Medical Public 11,412 (91.03) 1,124 (8.97) 0.0004
Facilities Private 29,651 (90.13) 3,247 (9.87)
Registration New 31,756 (91.86) 2,813 (8.14) < 0.0001
Type Relapse 4,772 (85.05) 839 (14.95)
T.A.F. 222 (78.45) 61 (21.55)
T.A.D. 490 (74.92) 164 (25.08)
T.I. 1,622 (89.51) 190 (10.49)
Other 2,201 (87.86) 304 (12.14)
TB type Sputum smear (þ)
pul TB
13,797 (87.63) 1,948 (12.37) < 0.0001
Sputum smear ()
pul TB
21,426 (91.28) 2,047 (8.72)
Extraepul TB 5,840 (93.95) 376 (6.05)
Medication Only Group 1 drugs 39,248 (90.69) 4,028 (9.31) <.0001
With Groups 2e5
drugs
1,815 (84.11) 343 (15.89)
Region 1 11,139 (92.17) 946 (7.83) < 0.0001
2 3,896 (85.99) 635 (14.01)
3 1,946 (90.30) 209 (9.70)
4 1,671 (90.13) 183 (9.87)
5 1,290 (93.07) 96 (6.93)
6 943 (89.98) 105 (10.02)
7 617 (90.60) 64 (9.40)
8 6,228 (92.31) 519 (7.69)
9 1,899 (89.15) 231 (10.85)
10 1,156 (91.38) 109 (8.62)
11 1,658 (90.06) 183 (9.94)
12 1,930 (91.86) 171 (8.14)
13 1,690 (86.84) 256 (13.16)
14 1,892 (89.84) 214 (10.16)
15 2,735 (86.63) 422 (13.37)
16 373 (93.02) 28 (6.98)
Total 41,063 (90.38) 4,371 (9.62)
Data are presented as n (%). T.A.D.Z treatment after default; T.A.F.Z treatment after failure; TBZ tuberculosis; T.I.Z transfer in; pulZ pulmonary.
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ment failure had the highest odds ratio of 3.18 (95% CI,
2.64e3.83), followed by first treatment failure [odds
ratio of 2.02 (95% CI, 1.50e2.72); and relapse regis-
tration [odds ratio of 1.76 (95% CI, 1.61e1.91)]. Move-
out and other reasons were associated with an odds ratio
of 1.23 (95% CI, 1.05e1.44) and 1.51 (95% CI,
1.33e1.71), respectively. Patients with sputum-positive
TB had more relapses, compared to patients with
sputum negative TB, with an odds ratio of 1.42 (95% CI,
1.33-1.52). Patients treated by Group 1 medicines hadmore relapses than patients treated by Groups 2e5
medicines with an odds ratio of 1.32 (95% CI,
1.16e1.50). The region also showed various associa-
tions (odds ratio of 0.85e1.85; Table 3).
For patients in public health centers, all dropout re-
cords were input and a multivariate logistic regression
was performed. Public health centers rarely used Group 2
medicines (< 1%); therefore, they were excluded in the
analysis. In the multivariate analysis among the patients
in public health centers, the relapse rate was not associ-
ated with age. This finding was different from the analysis
Table 3. Results of multivariate logistic regression
analysis.
OR (95% CI)
Sex Men 1.33 (1.24e1.43)
Women 1
Age (y) 0e9 0.43 (0.20e0.93)
10e19 1
20e29 1.07 (0.91e1.27)
30e39 1.10 (0.93e1.31)
40e49 1.20 (1.01e1.42)
50e59 1.02 (0.86e1.22)
60e69 1.04 (0.87e1.23)
70 0.90 (0.76e1.07)
Medical
facilities
Public 1
Private 1.23 (1.14e1.33)
Registration
type
New 1
Relapse 1.76 (1.61e1.91)
T.A.F. 2.02 (1.50e2.72)
T.A.D. 3.18 (2.64e3.83)
T.I. 1.23 (1.05e1.44)
Other 1.42 (1.25e1.61)
Tuberculosis
type
Sputum smear
(þ) pul TB
1.42 (1.33e1.52)
Sputum smear
() pul TB
1
Extrapulmonary TB 0.70 (0.62e0.78)
Medication Only Group 1 drugs 1
With Groups
2e5 drugs
1.32 (1.16e1.50)
Region 1 1
2 1.85 (1.66e2.06)
3 1.19 (1.02e1.42)
4 1.20 (1.01e1.42)
5 0.85 (0.69e1.06)
6 1.23 (0.99e1.52)
7 1.20 (0.92e1.57)
8 0.98 (0.87e1.10)
9 1.42 (1.21e1.65)
10 1.06 (0.86e1.30)
11 1.29 (1.09e1.53)
12 1.06 (0.90e1.26)
13 1.71 (1.47e1.99)
14 1.28 (1.09e1.50)
15 1.66 (1.47e1.88)
16 0.85 (0.58e1.26)
CIZ confidence interval; ORZ odds ratio; T.A.D.Z treatment after
default; T.A.F. Z treatment after failure; T.I. Z transfer in;
pul Z pulmonary.
Table 4. Results of multivariate logistic regression anal-
ysis in public health centers.
OR (95% CI)
Sex Men 1.32 (1.14e1.52)
Women 1
Age (y) 0e9 3.22 (0.32e32.27)
10e19 1
20e29 1.02 (0.78e1.35)
30e39 0.99 (0.75e1.32)
40e49 0.96 (0.73e1.28)
50e59 0.98 (0.73e1.33)
60e69 1.02 (0.76e1.38)
 70 0.81 (0.60e1.09)
Registration
type
New 1
Relapse 1.87 (1.60e2.18)
T.A.F. 3.35 (0.47e23.82)
T.A.D. 2.32 (1.64e3.29)
T.I. 1.09 (0.81e1.47)
Other 1.30 (0.85e1.98)
Tuberculosis
type
Sputum smear
(þ) pul TB
1.66 (1.45e1.88)
Sputum smear
() pul TB
1
Extrapulmonary
TB
0.81 (0.45e1.48)
Outcome Cure 1
Complete 1.39 (0.92e2.11)
Failure 10.26 (5.95e17.68)
Default 3.77 (3.03e4.68)
Transfer out 1.42 (1.17e1.73)
Other 2.41 (1.80e3.25)
Region 1 1
2 1.23 (0.96e1.58)
3 1.25 (0.89e1.75)
4 0.77 (0.54e1.09)
5 1.63 (1.03e2.57)
6 1.40 (0.94e2.09)
7 0.73 (0.40e1.31)
8 1.03 (0.84e1.28)
9 1.18 (0.84e1.68)
10 0.99 (0.68e1.45)
11 1.44 (1.05e1.97)
12 0.90 (0.62e1.30)
13 1.47 (1.10e1.96)
14 1.35 (1.02e1.79)
15 1.77 (1.35e2.32)
16 0.57 (0.30e1.09)
CI Z confidence interval; OR Z odds ratio; pul Z pulmonary;
T.A.F. Z treatment after failure, T.A.D. Z treatment after default,
T.I. Z transfer in.
S14 H. Lee, J. Kimwith total study subjects. The related variables [denoted
by (odds ratio, 95% CI)] were men (1.32, 1.14e1.52),
relapse (1.87, 1.60e2.18), and re-registration after cease
(2.32, 1.64e3.29). However, there was no association
with move-out or others. The treatment failure group was
too small to confirm significance. Sputum-positive TB
(1.66, 1.45e1.88), treatment failure (10.26, 5.95e17.68),
treatment cease (3.77, 3.03e4.68), move-out (1.42,
1.17e1.73), and other dropout (2.41, 1.80e3.25) were
associated with relapse (Table 4).4. Discussion
4.1. Interpretation of the results
This study aimed to identify factors associated with
relapse of TB in Korea by using national reported case
data. The relapse rate for a 5-year period in this study
was 9.6%, which was lower than the rate reported in the
Annual Report on the Notified Tuberculosis Patients in
Relapse of Tuberculosis in Korea S15Korea [3,4]. The relapse rate did not include relapse
after the 5-year period. The reported rate of private
medical institutions was estimated below 60%. The TB
infection of risk groups such as residents in unautho-
rized facilities and homeless people was not identified.
For various reasons, the relapse rate in this study was
underestimated in comparison to the annual reported
relapse rate. The relapse of TB can be divided into two
categories: (1) recurrence by reactivation of same bac-
teria in the previous infection and (2) reinfection. These
two factors can be confirmed with genotyping, but in
this study with national reported cases, the patients’
clinical data could not be attained; therefore, recurrence
and reinfection could not be identified [7,9]. Korea does
not conduct TB DNA finger printing tests on TB pa-
tients, and a special methodology is necessary to
distinguish between these two aspects. A literature re-
view indicates that within 2 years of treatment more
cases of recurrences result from reactivation of existing
bacteria and more cases of reinfection occur after 2
years of treatment with another person’s TB bacteria. A
high TB incidence rate is controversially associated with
reinfection [10,14]. In this study, 42% of the relapsed
TB patients had relapsed within 1 year and 65% of pa-
tients had relapsed within 2 years.
If we were to extend the follow-up period, the
relapse rate within 2 years would be lower. This finding
contrasted with the results of existing studies. A study
conducted in one private hospital revealed that 80% of
TB patients with completion of treatment needed addi-
tional treatment [8,9,15]. Compared to the existing
study in Korea, the relapse rate in 2 years after treat-
ment was lower and closer to the other country’s study
results [8,9,15].
The relapse of TB was higher in men, which is the
case with TB infection. The relapse rate by sex was
higher in some studies, but other studies show no rela-
tion [16,17]. This study also confirmed that men
relapsed more, based on Chi-square and multivariate
regression analyses. Relapse occurred more in patients
in the 40s, 50s, and 60s age groups. This may be asso-
ciated with the increase of TB patients and latent
tuberculosis infection. However, there was no relation
between age and the relapse rate in this study’s multi-
variate logistic regression with patients registered in the
public health centers with treatment results available.
This suggests that previous treatment results, rather than
age effect, affects the relapse of TB.
To confirm the same results in the all TB patients, it
is necessary to secure treatment results in patients
treated and controlled by private medical institutions.
Among patients using private medical institutions, the
relapse rate was higher compared to the rate of public
health centers. This finding could be explained in that
first infected TB patients treated by Group 1 medicines
were mostly treated in public health centers, whereas
incurable TB patients with relapsed TB or antimicrobial-resistant TB were treated in private medical institutions.
Furthermore, treatment dropout is also relatively higher
in private medical institutions [6].
Compared with new cases, relapsed patients, treat-
ment failure patients, and re-registered patients after
cease of treatment were more highly relapsed. It may
be that patients with second treatment are more
relapsed, compared to patients with new cases. In
particular, patients with treatment failure could be
relapsed again, even with full recovery after long-term
treatment. These results corresponded with the results
of existing studies that factor in relapse is previous TB
infection [14].
The relapse of patients with treatment failures were
also far higher (Tables 4 and 5). Treatment failure is
mostly attributable to antimicrobial-resistant tubercu-
losis. The relapse could be high, even after full recovery
after long-term treatment.
It could be a good method to lower the relapse by
managing the first TB-infected patients to take medicine
thoroughly and periodically not to fail treatment [15].
For convenience of intake, the everyday intake of
medicines is better for lowering TB relapse, compared
to taking medicines two or three times weekly. Directly
observed therapy (DOT) in general lowers the relapse
rate, but some researchers are suspicious of the effec-
tiveness of DOT [8,18]. The relapse rate with short-term
chemical therapy (e.g., rifampin) is < 5%; however, this
studys relapse rate of patients with full recovery using
public health centers with treatment results was 7.3%.
This rate was higher than the rate reported in existing
studies [19]. Patients with an irregular medicine intake
period, a cavity observed on chest X-ray, and sputum-
positive results after a 2 month-intake of medicine
have a relapse rate >5%; however, in this study, no
clinical data were secure and could not be confirmed
[18]. The completion patients’ relapse rate was 11.7%,
which is higher than the relapse rate of patients with full
recovery.
Without confirming negative TB, completion pa-
tients, who were in reality treatment failures, could be
reported as relapse patients [20]. Move-out patients also
showed a higher relapse rate. This may be because the
patients were no longer treated without move-in to other
medical institutions. However, more study on confor-
mity is needed.
4.2. Strength and limitations
Studies outside Korea indicate relapse factors of TB
such as irregular intake of medicine, alcoholism,
smoking, previous history of TB infection, and dis-
eases accompanied by a decline in immunocompetence
[15]. This study could not investigate the associated
factors of behavior or clinical situations of patients and
did not confirm factors. Furthermore, no questionnaires
were conducted to investigate the behaviors and so-
cioeconomic characteristics of patients and this study
Table 5. Relapse rate of tuberculosis in public health centers.
Relapse
p
No Yes
Sex Men 7,511 (90.0) 839 (10.0) < 0.0001
Women 3,901 (93.2) 285 (6.8)
Age (y) 0e9 4 (80.0) 1 (20.0) 0.002
10e19 1,115 (93.5) 78 (6.5)
20e29 2,377 (91.6) 218 (8.4)
30e39 1,855 (90.7) 190 (9.3)
40e49 1,762 (89.8) 200 (10.2)
50e59 1,195 (89.7) 138 (10.3)
60e69 1,411 (90.0) 156 (10.0)
 70 1,693 (92.2) 143 (7.8)
Registration New 8,684 (92.5) 705 (7.5) < 0.0001
Type Relapse 1,655 (85.1) 289 (14.9)
T.A.F 3 (60.0) 2 (40.0)
T.A.D 178 (78.8) 48 (21.2)
T.I 677 (92.6) 54 (7.4)
Other 215 (89.2) 26 (10.8)
TB type Sputum smear (þ)
pul TB
4,585 (88.2) 616 (11.8) < 0.0001
Sputum smear ()
pul TB
6,615 (93.0) 496 (7.0)
Extrapulmonary TB 212 (94.6) 12 (5.4)
Outcome Cure 9,366 (92.7) 735 (7.3) < 0.0001
Complete 217 (88.9) 27 (11.1)
Failure 28 (50.0) 28 (50.0)
Default 428 (76.0) 135 (24.0)
Transfer out 1,083 (88.6) 139 (11.4)
Other 290 (82.9) 60 (17.1)
Region 1 2,109 (91.54) 195 (8.46) 0.0002
2 967 (89.37) 115 (10.63)
3 430 (89.77) 49 (10.23)
4 606 (93.66) 41 (6.34)
5 212 (89.83) 24 (10.17)
6 277 (89.35) 33 (10.65)
7 223 (94.49) 13 (5.51)
8 2,422 (92.09) 208 (7.91)
9 468 (90.87) 47 (9.13)
10 438 (92.41) 36 (7.59)
11 539 (89.68) 62 (10.32)
12 491 (92.99) 37 (7.01)
13 667 (89.65) 77 (10.35)
14 716 (89.50) 84 (10.50)
15 655 (87.68) 92 (12.32)
16 192 (94.58) 11 (5.42)
Total 11,412 (91.0) 1,124 (9.0)
Data are presented as n (%). pul Z pulmonary; T.A.D. Z treatment after default, T.A.F. Z treatment after failure; T.I. Z transfer in.
S16 H. Lee, J. Kimhas limited variables [15]. Private medical institution
had limited results after dropout of the registry;
therefore, no relapse rate was calculated for the
dropout patients.
Medical doctors and medical institution are required
to report TB patients, but it is not mandatory to report
treatment and control of TB patients. To overcome this
limit, the National Health Insurance data should be uti-
lized for the visit period, TB bacteria test date, medicineintake information, insurance type, and insurance pre-
mium. This current study’s limitation would also be
overcome by surveying a sample representative popula-
tion to cover health behavior and socioeconomic status.
In the disease code after 2008, multidrug-resistant TB
and extensively drug-resistant TB were introduced as
“U88.0” and “U88.1”, respectively. Using reported cases
after 2008, a study on the relapse of antimicrobial-
resistant TB patients could be conducted, which this
Relapse of Tuberculosis in Korea S17study did not investigate. However, this study has a
strong point in that it secured representativeness and
confidence of data by using national TB reported cases,
and calculated the relapse rate of tuberculosis in Korea,
and identified factors associated with relapse of TB.Conflicts of interest
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